ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2723

The Co-Occurrence of Axial Spondyloarthritis and Fibromyalgia: A National Register-Based Study

Gary J. Macfarlane1,2, Maxwell S. Barnish1,3 and Gareth T. Jones3,4, 1Epidemiology Group, University of Aberdeen, Aberdeen, United Kingdom, 2Aberdeen Centre for Arthritris and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, 3Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, 4Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: axial spondyloarthritis and fibromyalgia, Co-morbidities

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Some patients with axial spondyloarthritis (axSpA) are recognized clinically to have co-morbid fibromyalgia (FM). However, there are no trials to inform how these patients are best managed when axSpA and FM occur together. This study aims to provide data on their frequency of co-occurrence and, amongst persons with axSpA, features which characterize persons with co-morbid FM

Methods: The British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) recruits persons meeting any ASAS definition of axSpA. All patients recruited are naïve to biologic therapy and are either newly starting biologic therapy (biologic cohort) or not (non-biologic cohort). At recruitment, patients self-complete the ACR 2010 modified research criteria (2010m ACR) for FM, Bath measures of disease activity (BASDAI), function (BASFI) and global severity (BAS-G), Quality of Life (ASQoL and EQ-5D), sleep disturbance score (SDS), Chalder Fatigue Scale (CFS), and Hospital Anxiety and Depression Scale (HADS). Clinicians indicated whether they had made a clinical diagnosis of FM; Bath metrology index (BASMI) and Body Mass Index (BMI) were measured. The Index of Multiple Deprivation (IMD) is an area based measure of deprivation based on postcode.

Results: 430 patients provided clinical information and the recruting clinicians considered that 13 had a clinical diagnosis of FM (3.0%), while 274 provided self-report data, of whom 56 (20.4%) met the 2010m ACR FM criteria. Patients who met FM criteria were more likely to be female (difference in proportion 0.21; 95% CI (0.07, 0.36), reported worse BASDAI (mean difference (md) 2.7; 95% CI 2.0, 3.3), BASFI (md 2.7; 1.9, 3.4) and BAS-G (md 2.7; 2.0, 3.5). They reported worse Quality of Life (ASQoL md 6.3; 4.8, 7.8: EQ-5D md -0.23; -0.32,-0.14), higher levels of anxiety (md 3.9; 2.7, 5.1) and depression (md 4.0; 2.9, 5.2), more sleep problems (md 3.7; 2.0, 5.4) and higher levels of fatigue (md 4.0; 3.0, 5.0). There was no difference in age, IMD or whether they were commencing biologic therapy.

Conclusion: There is a large discrepancy between clinical diagnosis of FM and meeting FM research criteria in patients with axSpA. Patients who meet FM criteria show markedly worse markers of axSpA disease activity and generally poorer health. It is unknown whether such criteria are valid in the presence of axSpA, but there may be a large unmet and unrecognised need for treatment of FM symptoms amongst patients with axSpA.  


Disclosure: G. J. Macfarlane, Pfizer Inc; AbbVie; UCB, 2; M. S. Barnish, None; G. T. Jones, Pfizer Inc, AbbVie, UCB, 2.

To cite this abstract in AMA style:

Macfarlane GJ, Barnish MS, Jones GT. The Co-Occurrence of Axial Spondyloarthritis and Fibromyalgia: A National Register-Based Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-co-occurrence-of-axial-spondyloarthritis-and-fibromyalgia-a-national-register-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-co-occurrence-of-axial-spondyloarthritis-and-fibromyalgia-a-national-register-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology